Rate My Professor Shahram Kordasti

Kordasti’s research centers on the role of the immune system in bone marrow failure syndromes and myeloid malignancies, with a focus on the plasticity of CD4+ T cells—including regulatory T cells (Tregs) and Th17 cells—their interactions with inflammatory microenvironments, and immune dysregulation driving disease progression from MDS to acute leukaemia. He established the key role of Tregs in myelodysplastic syndromes (MDS) and aplastic anaemia (AA), shaping insights into treatment responses and advancing translational studies, including the first-in-human Phase I trial of autologous regulatory T cells for immune aplastic anaemia (Matto et al., Haematologica, 2026). Additional key publications include 'Prognostic value of flow cytometry in myelodysplastic neoplasms: Composition of a FCM-prognostic score (FCM-PS) for overall survival' (Santaolalla et al., HemaSphere, 2026), 'Characterization and Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes' (Kordasti et al., Journal of Clinical Oncology, 2025), and a chapter on 'Cancer immunotherapy' in Hoffbrand’s Postgraduate Haematology (O'Brien-Gore et al., 2025). Employing multidimensional cytometry (CyTOF), computational biology, and multiomics integration, his work identifies immune signatures for predicting progression and therapy outcomes, alongside exploring cell therapy strategies like Treg expansion. With 3,880 citations, he chairs the European Haematology Association Specialised Working Group on MDS, leads the i4MDS international consortium for standardizing immune monitoring, serves as Editor for Frontiers in Immunology since 2018, and delivered his inaugural lecture 'From T-rex to Tregs: An “Accidental” Professor’s Deliberate Path' in February 2026.